A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

Medicare and Medicaid move toward covering Ozempic and other weight loss drugs - The proposed plan could go into effect as early as next April for those on Medicaid ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

Entrepreneurship raises your risk of obesity, but small changes to your diet can have similar affects to new weight-loss ...